Immune-mediated thrombotic thrombocytopenic purpura in childhood treated by caplacizumab, about 3 cases.
J Nephrol
; 35(2): 653-656, 2022 Mar.
Article
em En
| MEDLINE
| ID: mdl-33616856
ABSTRACT
Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a rare disease in adults and exceptional in childhood. Caplacizumab has proven its effectiveness in the treatment of iTTP in adulthood in association with standard of care. Unfortunately, this treatment is restricted to adults. We report our experience in three children who were treated successfully with caplacizumab.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Púrpura Trombocitopênica Trombótica
/
Anticorpos de Domínio Único
Tipo de estudo:
Diagnostic_studies
Limite:
Adult
/
Child
/
Humans
Idioma:
En
Revista:
J Nephrol
Ano de publicação:
2022
Tipo de documento:
Article